TNFRSF18 Antikörper (FITC)

Produktnummer ABIN2661689

Produktdetails anti-TNFRSF18 Antikörper (FITC)

Target: TNFRSF18 (Tumor Necrosis Factor Receptor Superfamily, Member 18 (TNFRSF18))

Reaktivität: Maus

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser TNFRSF18 Antikörper ist konjugiert mit FITC

Applikation: Flow Cytometry (FACS), Western Blotting (WB), Immunohistochemistry (IHC)

Aufreinigung: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC.

Klon: YGITR 765

Isotyp: IgG2b kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu TNFRSF18

Target: TNFRSF18 (Tumor Necrosis Factor Receptor Superfamily, Member 18 (TNFRSF18))

Andere Bezeichnung: CD357 (TNFRSF18 Produkte)

Synonyme: GITR antikoerper, TNFRSF18 antikoerper, AITR antikoerper, Gitr antikoerper, CD357 antikoerper, GITR-D antikoerper, TNF receptor superfamily member 18 antikoerper, tumor necrosis factor receptor superfamily, member 18 antikoerper, TNFRSF18 antikoerper, Tnfrsf18 antikoerper

Hintergrund: GITR, Glucocorticoid-induced TNFR-related gene, is a member of the TNF receptor superfamily, also known as TNFRSF18, and AITR (in humans). It is expressed at low levels on resting T lymphocytes and at high levels on CD4+ CD25+ T regulatory (Treg) cells. The expression of GITR on T cells can be upregulated upon activation. Interaction of GITR with its ligand (GITRL) has been demonstrated to augment T cell activation, proliferation, cytokine production, as well as MAPKs and NF-κB activation, and abrogate the inhibitory functions of CD4+CD25+ Treg cells. In vivo activation GITR causes development of autoimmune diseases and restores the suppressed immune responses.

Pathways: Cancer Immune Checkpoints